质量改进干预对急性缺血性卒中患者再灌注治疗的效果:阶梯楔形整群随机临床试验
该阶梯楔形整群随机临床试验在中国16家二级和33家三级医院连续纳入症状发作6小时内的急性缺血性卒中患者,共12132例完成试验。干预为流程重建以减少院内再灌注治疗延迟(n=5689),对照为常规卒中诊疗(n=6443)。主要终点再灌注率干预期53.5% vs 对照期43.9%,校正后ARD 5.5%(95%CI -8.0%至19.0%)、AOR 1.26(95%CI 0.72-2.21),未达统计学显著;次要终点亦无显著改善。亚组分析显示二级医院再灌注治疗、IV rtPA给药和EVT均有显著改善。作者认为该干预可能对二级医院有效。
要点
- 总体人群:干预期再灌注率53.5%(3046/5689)vs 对照期43.9%(2830/6443),校正后ARD 5.5%(95%CI -8.0%至19.0%)、AOR 1.26(95%CI 0.72-2.21),未达统计学显著。
- 二级医院亚组:再灌注治疗57.8%(1081/1870)vs 42.9%(945/2022),ARD 19.0%(95%CI 6.4%-31.6%)、AOR 2.24(95%CI 1.29-3.88)。
- 二级医院亚组:IV rtPA给药58.2%(1062/1826)vs 42.2%(916/2170),ARD 20.3%(95%CI 7.4%-33.1%)、AOR 2.37(95%CI 1.34-4.19)。
- 二级医院亚组:EVT 22.1%(51/231)vs 14.3%(37/259),ARD 13.6%(95%CI 1.0%-26.3%)、AOR 3.03(95%CI 1.11-8.25)。
- 作者结论:针对性质量改进干预与常规诊疗相比未改善再灌注治疗率,但该干预可能在二级医院有效。
适用人群与场景
- 中国16家二级和33家三级医院中,症状发作6小时内的急性缺血性卒中患者,于2018年7月1日至2020年6月30日连续纳入。
- 主要终点分析人群为症状发作3.5或4.5小时内到达的符合再灌注治疗条件的患者。
处置流程与药物剂量
- 干预措施为流程重建,以缩短院内再灌注治疗延迟;对照期常规卒中诊疗由卒中团队自行决定。
- 主要终点再灌注治疗定义为符合条件患者在症状发作3.5或4.5小时内到达后接受静脉重组组织型纤溶酶原激活剂(IV rtPA)或血管内取栓(EVT)。
研究设计与关键结果
- 研究类型:阶梯楔形整群随机临床试验;样本量12132例符合条件患者(平均[SD]年龄66[12.1]岁;男性7759例[64.0%]);16家二级和33家三级医院。
- 主要终点:再灌注率干预期53.5%(3046/5689)vs 对照期43.9%(2830/6443),校正整群、时期和不平衡基线协变量后ARD 5.5%(95%CI -8.0%至19.0%)、AOR 1.26(95%CI 0.72-2.21),未达统计学显著。
- 次要终点:IV rtPA给药率、EVT率、门-针时间60分钟内比例、门-穿刺时间90分钟内比例、院内死亡率、3个月残疾(改良Rankin量表评分大于2)均无显著改善。
- 亚组分析二级医院:再灌注治疗57.8%(1081/1870)vs 42.9%(945/2022),ARD 19.0%(95%CI 6.4%-31.6%)、AOR 2.24(95%CI 1.29-3.88)。
- 亚组分析二级医院:IV rtPA给药58.2%(1062/1826)vs 42.2%(916/2170),ARD 20.3%(95%CI 7.4%-33.1%)、AOR 2.37(95%CI 1.34-4.19)。
- 亚组分析二级医院:EVT 22.1%(51/231)vs 14.3%(37/259),ARD 13.6%(95%CI 1.0%-26.3%)、AOR 3.03(95%CI 1.11-8.25)。
证据类型、等级与局限
- 证据类型:阶梯楔形整群随机临床试验;试验注册号ClinicalTrials.gov NCT03578107。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在中国急性缺血性卒中患者中,针对性质量改进干预与常规诊疗相比未改善再灌注治疗率,但该干预可能在二级医院有效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Reperfusion therapy is the most effective treatment for acute ischemic stroke but remains underused in China.
OBJECTIVE: To evaluate the effect of a problem-oriented, culturally adapted, targeted quality improvement intervention on reperfusion therapy for patients with acute ischemic stroke in China.
DESIGN, SETTING, AND PARTICIPANTS: In this stepped-wedge cluster randomized clinical trial, patients from 16 secondary and 33 tertiary hospitals in China with acute ischemic stroke within 6 hours of symptom onset were consecutively recruited between July 1, 2018, and June 30, 2020.
INTERVENTIONS: Hospitals were randomly assigned to 1 of 3 sequences to receive the targeted quality improvement intervention (n = 5689), in which workflow reconstruction was promoted to reduce in-hospital reperfusion treatment delays, or usual care (n = 6443), in which conventional stroke care was left to the discretion of the stroke team.
MAIN OUTCOMES AND MEASURES: The primary outcome was the reperfusion therapy rate, a composite outcome of intravenous recombinant tissue plasminogen activator (IV rtPA) or endovascular thrombectomy (EVT) for eligible patients who arrived within 3.5 or 4.5 hours of symptom onset. Secondary outcomes were the IV rtPA administration rate among eligible patients who arrived within 3.5 hours of symptom onset, the EVT rate among eligible participants who arrived within 4.5 hours of symptom onset, the proportion of patients with door-to-needle time within 60 minutes, the proportion of patients with door-to-puncture time within 90 minutes, in-hospital mortality, and 3-month disability as measured by a modified Rankin Scale score greater than 2.
RESULTS: All 12 132 eligible patients (mean [SD] age, 66 [12.1] years; 7759 male [64.0%]) completed the trial. The reperfusion rate was 53.5% (3046 of 5689) for the eligible patients in the intervention period and 43.9% (2830 of 6443) in the control period. No significant improvement in primary outcomes was found for the intervention after adjusting for cluster, period, and imbalanced baseline covariates (adjusted risk difference [ARD], 5.5%; 95% CI, -8.0% to 19.0%; adjusted odds ratio [AOR], 1.26; 95% CI, 0.72-2.21) or for the secondary outcomes. However, significant improvements were found in secondary hospitals for reperfusion therapy (1081 of 1870 patients [57.8%] vs 945 of 2022 patients [42.9%]; ARD, 19.0%; 95% CI, 6.4%-31.6%; AOR, 2.24; 95% CI, 1.29-3.88), IV rtPA administration (1062 of 1826 patients [58.2%] vs 916 of 2170 patients [42.2%]; ARD, 20.3%; 95% CI, 7.4%-33.1%; AOR, 2.37; 95% CI, 1.34-4.19), and EVT (51 of 231 patients [22.1%] vs 37 of 259 patients [14.3%]; ARD, 13.6%; 95% CI, 1.0%-26.3%; AOR, 3.03; 95% CI, 1.11-8.25) in subgroup analyses.
CONCLUSIONS AND RELEVANCE: In this stepped-wedge cluster randomized clinical trial of patients with acute ischemic stroke in China, the use of a targeted quality improvement intervention compared with usual care did not improve the reperfusion therapy rate. However, the intervention may be effective in secondary hospitals.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03578107.
参考来源
- Wang CJ, Gu HQ, Zong LX, et al. Effectiveness of a Quality Improvement Intervention on Reperfusion Treatment for Patients With Acute Ischemic Stroke: A Stepped-Wedge Cluster Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37266940. doi:10.1001/jamanetworkopen.2023.16465
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。